1. Introduction

Competition Law in Vaccine Route Allocation in Morocco concerns the regulation of agreements, distribution arrangements, transportation networks, procurement systems and market-allocation practices involving the transportation and delivery of vaccines throughout Morocco.

Vaccine route allocation refers to the process by which pharmaceutical manufacturers, vaccine distributors, logistics companies, wholesalers, cold-chain operators and public authorities determine:

Which company will transport vaccines to particular regions.

Which distributors will supply particular hospitals and vaccination centres.

Which logistics operators will receive regional delivery territories.

Whether exclusive transportation routes will be granted to selected companies.

How vaccine delivery contracts and public procurement opportunities will be distributed.

Whether competing pharmaceutical and logistics companies can access essential distribution infrastructure.

The central competition-law concern is that allocating delivery routes may be commercially necessary for efficient vaccine distribution, but agreements that divide territories, exclude competitors, manipulate tenders or restrict access to distribution infrastructure can undermine competition.

In Morocco, this subject must be examined principally under Law No. 104-12 on Freedom of Prices and Competition, together with its amendments, particularly Law No. 40-21, and the institutional framework governing the Moroccan Competition Council.

An important distinction is that legitimate public-health coordination is not automatically an infringement of competition law. The legal issue is whether the arrangement is objectively necessary, proportionate and compatible with competitive market conditions.

2. Legal Framework Governing Vaccine Route Allocation in Morocco

A. Law No. 104-12 on Freedom of Prices and Competition

This legislation establishes the principal rules governing restrictive agreements and abuse of dominant positions.

Article 6 – Anti-competitive agreements

Article 6 prohibits agreements, concerted practices and arrangements that have as their object or effect the prevention, restriction or distortion of competition in a market.

In vaccine route allocation, potential infringements include:

Competing distributors agreeing to divide Moroccan regions.

Logistics companies agreeing not to compete for particular vaccine routes.

Pharmaceutical suppliers allocating hospitals among themselves.

Distributors agreeing on transportation prices.

Companies coordinating bids for government vaccine-delivery contracts.

Competitors agreeing to exclude independent cold-chain operators.

For example, if three vaccine distributors agree that one will serve Casablanca, another Rabat and a third Marrakech, while promising not to enter one another's territories, the arrangement may constitute prohibited market allocation.

Article 7 – Abuse of dominant position

Article 7 addresses abusive conduct by undertakings holding a dominant position.

Potential abuses include:

Refusing access to essential cold-storage facilities without objective justification.

Discriminating between competing vaccine distributors.

Imposing unfair contractual conditions.

Restricting access to strategically important transportation routes.

Using exclusive distribution agreements to foreclose competitors.

Conditioning vaccine transportation services on purchasing unrelated services.

Dominance itself is not prohibited. The concern is its abusive exploitation.

Merger control

The merger-control provisions of Law No. 104-12 must also be considered where acquisitions or combinations involving vaccine logistics companies, pharmaceutical distributors or cold-chain infrastructure meet the applicable notification requirements.

B. Law No. 20-13 on the Competition Council

Law No. 20-13 establishes the institutional framework of the Moroccan Competition Council.

The Council plays an important role in:

Investigating restrictive agreements.

Examining allegations of dominant-position abuse.

Reviewing relevant economic concentrations.

Issuing opinions and recommendations.

Protecting competitive market structures.

C. Public Procurement Rules

Vaccine transportation contracts awarded by public authorities may also raise procurement-law concerns.

Competition problems may arise where bidders coordinate their offers, divide delivery regions, submit cover bids or agree to rotate successful contracts.

D. Pharmaceutical and Public-Health Regulation

Competition law must operate alongside Moroccan pharmaceutical, public-health, medicine-distribution, transport and cold-chain requirements.

A vaccine route allocation system must therefore satisfy both competition requirements and legitimate public-health obligations, including product integrity, temperature control, traceability and timely delivery.

3. Meaning and Types of Anti-Competitive Vaccine Route Allocation

A. Geographic market allocation

This occurs when competing vaccine distributors agree to divide geographical territories.

Example:

Company A receives exclusive vaccine distribution rights in northern Morocco.

Company B receives exclusive rights in central Morocco.

Company C receives exclusive rights in southern Morocco.

If competitors independently choose efficient delivery areas, the arrangement may be legitimate. However, if they agree not to compete against each other, the arrangement can violate Article 6.

B. Exclusive vaccine transportation routes

A pharmaceutical manufacturer may appoint one logistics operator to transport vaccines along specified routes.

Exclusive arrangements can be justified by:

Temperature-control requirements.

Vaccine safety and integrity.

Delivery reliability.

Specialised refrigerated vehicles.

Traceability and monitoring requirements.

However, exclusivity becomes problematic where it unnecessarily prevents competing logistics companies from accessing the market.

C. Hospital and vaccination-centre allocation

Competing distributors may agree to supply different hospitals, clinics or vaccination centres.

For example, two distributors might agree that one will serve public hospitals while the other serves private hospitals.

Such arrangements require particular scrutiny if they eliminate competition for institutional customers.

D. Public tender allocation

Government authorities may divide vaccine transportation contracts into geographical or operational lots.

This is not inherently unlawful. Indeed, dividing contracts into lots can increase participation by smaller logistics companies.

However, competing bidders must not privately agree on:

The winning bidder for each region.

Which company will abstain from bidding.

The prices submitted for individual routes.

The distribution of profits through subcontracting.

The rotation of successful bidders.

E. Cold-chain infrastructure allocation

Vaccine distribution depends on refrigerated warehouses, temperature-monitoring equipment, specialised vehicles and qualified storage facilities.

A dominant operator controlling essential infrastructure could potentially use that position to exclude competing logistics providers.

F. Digital route allocation

Modern vaccine distribution may use software to allocate vehicles, calculate delivery schedules, identify vaccination centres and monitor transportation.

Competition concerns arise when competing operators use a common digital platform to exchange commercially sensitive information or coordinate geographical territories.

4. Important Competition-Law Issues

A. Market definition

The relevant market should be defined carefully.

There may be several separate markets:

Vaccine manufacturing and supply.

Wholesale distribution of vaccines.

Specialised pharmaceutical transportation.

Refrigerated vaccine storage.

Temperature-monitoring and traceability services.

Public procurement of vaccine logistics services.

The geographical market may be national, regional or narrower, depending on competitive conditions, regulatory requirements, transportation costs and available alternatives.

For example, a company controlling refrigerated vaccine storage in a particular region may have significant local market power even if several competitors operate nationally.

B. Effects on competition

Authorities should investigate whether route allocation:

Reduces the number of competing distributors.

Increases transportation prices.

Restricts access for independent logistics operators.

Creates regional monopolies.

Reduces service quality.

Prevents innovation in cold-chain technology.

Makes public procurement less competitive.

Creates dependence on a single logistics provider.

C. Public-health justification

Vaccine transportation is different from ordinary commercial distribution.

A route arrangement may be necessary to ensure:

Continuous refrigeration.

Rapid delivery to remote communities.

Emergency vaccine distribution.

Prevention of spoilage.

Reliable regional coverage.

Compliance with pharmaceutical safety requirements.

Article 9 of Law No. 104-12 is particularly important. It provides for exceptions to Articles 6 and 7 in specified circumstances, including agreements contributing to economic or technical progress, provided that users receive a fair share of the resulting benefits and the restrictions are indispensable and do not eliminate competition for a substantial part of the market.

Therefore, a vaccine route-sharing arrangement should be supported by measurable public-health and logistical benefits rather than a general assertion that cooperation is necessary.

5. At Least 6 Important Case Laws

Important legal qualification: The following are comparative competition-law precedents, principally from European Union and United States jurisdictions. They are persuasive analytical references for Moroccan competition-law discussions, not binding Moroccan judgments. They do not establish that Morocco has already adjudicated an identical vaccine route-allocation dispute.

Case 1. Consten and Grundig v Commission (1966)

EU COURT OF JUSTICE · JOINED CASES 56/64 AND 58/64

Facts: Grundig appointed Consten as its exclusive distributor in France. The distribution arrangement provided strong territorial protection against parallel imports and competing distributors.

Legal issue: Whether agreements providing absolute territorial protection could restrict competition.

Judgment: The Court recognised that agreements designed to eliminate parallel trade and protect exclusive territories could violate competition rules.

Application to Morocco:

If competing vaccine manufacturers or distributors agree to divide Moroccan regions and prevent cross-territorial competition, the arrangement may constitute prohibited market allocation.

Legal principle: Exclusive distribution cannot be used as a mechanism for eliminating competition between independent businesses.

Case 2. Société Technique Minière v Maschinenbau Ulm (1966)

EU COURT OF JUSTICE · CASE 56/65

Facts: The dispute concerned an exclusive distribution arrangement involving machinery and restrictions affecting sales outside the allocated territory.

Legal issue: Whether an exclusive distribution agreement necessarily restricts competition.

Judgment: The Court explained that the competitive effects of an agreement must be assessed in its economic and legal context, including the nature of the products, market structure and actual competitive conditions.

Application to Morocco:

An exclusive vaccine transportation contract should not automatically be treated as unlawful.

Authorities should consider whether the arrangement:

Improves delivery efficiency.

Protects vaccine quality.

Creates genuine operational advantages.

Restricts competing logistics operators unnecessarily.

Legal principle: Exclusive agreements require contextual economic assessment.

Case 3. United Brands Company v Commission (1978)

EU COURT OF JUSTICE · CASE 27/76

Facts: United Brands held a strong position in the banana market and imposed restrictive commercial conditions on its distributors.

Legal issue: Whether a dominant undertaking could impose abusive commercial conditions and restrict distribution relationships.

Judgment: The Court examined the company's dominant position and abusive conduct, including discriminatory and restrictive commercial practices.

Application to Morocco:

Suppose a dominant pharmaceutical logistics company controls most specialised vaccine-storage facilities and provides access only to distributors agreeing not to work with rival transport operators.

Such behaviour could raise concerns under Article 7.

Legal principle: Dominant companies must not use their market power to impose abusive distribution conditions.

Case 4. Commercial Solvents v Commission (1974)

EU COURT OF JUSTICE · JOINED CASES 6/73 AND 7/73

Facts: Commercial Solvents controlled an important raw material used in pharmaceutical production and discontinued supplies to a customer competing in a downstream market.

Legal issue: Whether a dominant undertaking could refuse supplies to eliminate competition in a downstream market.

Judgment: The Court found that the refusal to supply could constitute an abuse of dominant position where it threatened to eliminate competition in the downstream market.

Application to Morocco:

A dominant cold-chain infrastructure operator that refuses essential warehouse or refrigerated transportation access to competing vaccine distributors could face scrutiny.

However, the availability of alternative infrastructure and the objective necessity of access must be established.

Legal principle: Refusal to supply essential inputs may constitute abusive exclusion.

Case 5. Oscar Bronner GmbH v Mediaprint (1998)

EU COURT OF JUSTICE · CASE C-7/97

Facts: A newspaper publisher sought access to a competitor's extensive home-delivery distribution network.

Legal issue: Whether a dominant company must provide competitors with access to infrastructure that it owns or operates.

Judgment: The Court established a demanding test for compulsory access, including whether the infrastructure was indispensable and whether refusal was capable of eliminating effective competition.

Application to Morocco:

A vaccine distributor seeking access to a rival's refrigerated transportation network cannot establish an Article 7 infringement merely by demonstrating that access would be convenient.

It must establish the relevant market conditions, lack of realistic alternatives and the other requirements for an abusive refusal.

Legal principle: Not every refusal to share infrastructure is unlawful; indispensability and exclusionary effects are important.

Case 6. T-Mobile Netherlands BV and Others (2009)

EU COURT OF JUSTICE · CASE C-8/08

Facts: Competing mobile telecommunications operators exchanged commercially sensitive information during a meeting concerning future commercial conduct.

Legal issue: Whether an exchange of commercially sensitive information could constitute an anti-competitive concerted practice.

Judgment: The Court explained that information exchange capable of reducing strategic uncertainty between competitors can infringe competition law.

Application to Morocco:

Competing vaccine logistics providers must not exchange confidential information concerning:

Future transportation prices.

Regional delivery bids.

Intended geographical territories.

Future customer allocation.

Planned capacity restrictions.

A shared vaccine logistics platform should be designed to prevent the exchange of competitively sensitive information between competing operators.

Legal principle: Competitors must independently determine their commercial strategy.

Case 7. United States v Sealy, Inc. (1967)

UNITED STATES SUPREME COURT · 388 U.S. 350

Facts: Sealy operated a mattress licensing and distribution system involving territorial restrictions imposed on licensees.

Legal issue: Whether territorial restrictions could constitute unlawful market allocation.

Judgment: The Supreme Court examined the territorial restrictions as part of an unlawful market-allocation arrangement.

Application to Morocco:

If competing vaccine distributors establish a territorial system under which each company receives an exclusive region and agrees not to compete elsewhere, the arrangement may resemble the prohibited conduct examined in Sealy.

Legal principle: Territorial distribution structures can conceal agreements that divide markets among competitors.

Case 8. Palmer v BRG of Georgia, Inc. (1990)

UNITED STATES SUPREME COURT · 498 U.S. 46

Facts: Two competing bar-review businesses agreed to divide geographical territories, with each business agreeing not to compete in the other's allocated territory.

Legal issue: Whether a geographical market-allocation agreement between competitors violates competition law.

Judgment: The Supreme Court treated the territorial division as a per se unlawful market-allocation agreement under US antitrust law.

Application to Morocco:

If vaccine logistics companies agree that one will handle northern routes and another will handle southern routes, without independently competing for contracts, the arrangement could raise serious Article 6 concerns.

Legal principle: Direct agreements between competitors to divide geographical markets are particularly serious competition restrictions.

6. Particularly Relevant Vaccine Distribution Enforcement Examples

Apart from judicial precedents, two competition-enforcement examples are especially relevant.

A. Febelco and Pharma Belgium-Belmedis vaccine cartel (Belgium, 2022)

Direct vaccine-sector relevance

The Belgian Competition Authority sanctioned pharmaceutical wholesalers Febelco and Pharma Belgium-Belmedis for cartel conduct involving pharmaceutical distribution and influenza vaccines.

The companies coordinated commercial conditions, including discounts and the treatment of unsold vaccines during advance-sales periods.

Pharma Belgium-Belmedis received a fine of approximately €29.8 million, while Febelco received immunity after disclosing the cartel.

Relevance to Morocco: This demonstrates that coordination between vaccine distributors can be anti-competitive even when it does not involve an explicit geographical division of delivery routes.

EUR-Lex+1

B. Spanish radiopharmaceutical market-sharing investigation

Spanish competition authorities sanctioned Advanced Accelerator Applications Ibérica and Curium Pharma Spain for coordinating their participation in supply tenders for PET radiopharmaceuticals.

The companies used bid coordination and subcontracting arrangements to divide supply opportunities rather than compete independently.

Relevance to Morocco: Similar conduct could occur when vaccine logistics companies coordinate bids for regional transportation contracts and subsequently subcontract work between themselves.

EUR-Lex

These examples are enforcement decisions rather than Moroccan vaccine-route judgments.

7. Application to Different Vaccine Distribution Scenarios in Morocco

8. Responsibilities of the Moroccan Competition Council

The Competition Council should consider the following issues when examining vaccine route allocation.

A. Investigation of geographical allocation

The Council may examine whether competitors have agreed to allocate delivery territories, hospitals or vaccination centres.

B. Examination of public procurement

It should investigate suspicious tender patterns, including:

Identical or unusually similar bids.

Repeated regional allocation among the same companies.

Bid withdrawals.

Cover bidding.

Unexplained subcontracting between unsuccessful and successful bidders.

C. Examination of dominant operators

Where one undertaking controls important cold-chain infrastructure, the Council should investigate whether access restrictions are objectively justified or designed to exclude competitors.

D. Examination of digital platforms

The Council should examine whether common logistics platforms facilitate independent operational coordination or instead enable competitors to exchange confidential pricing, capacity and customer information.

The Moroccan institutional framework empowers the Competition Council to address anti-competitive practices and economic concentration.

Conseil de la concurrence du Maroc+1

9. Legal Remedies and Possible Penalties

Where an infringement is established, the consequences may include:

Termination of unlawful agreements: Competitors may be required to stop agreements dividing vaccine delivery territories.

Removal of restrictive clauses: Unjustified exclusivity and non-compete provisions may need to be removed.

Financial penalties: Monetary sanctions may be imposed under the applicable provisions of Law No. 104-12.

Merger remedies: Relevant concentrations may be subject to conditions or corrective measures.

Restoration of competitive access: Access arrangements may be reconsidered where exclusionary conduct is established.

Public procurement consequences: Bid-rigging conduct may also trigger consequences under applicable procurement and other laws.

Judicial remedies: Relevant agreements and clauses may face civil-law consequences, including nullity where the statutory requirements are satisfied.

The exact penalty depends on the applicable statutory provisions, the nature and duration of the infringement, the undertaking's circumstances and the procedural safeguards.

10. Compliance Framework for Vaccine Route Allocation Companies

A Moroccan vaccine distribution company should establish the following compliance safeguards.

Recommended model for Morocco

A legally safer vaccine distribution model would include:

Competitive procurement of transportation services.

Geographical lots based on logistical efficiency.

Transparent eligibility requirements.

Objective cold-chain performance standards.

Non-discriminatory access to distribution infrastructure where legally required.

Independent bidding by logistics companies.

Limited and documented emergency cooperation.

Regular review of exclusive transportation arrangements.

This model can support both vaccine safety and competition.

11. Critical Legal Analysis

The central challenge is balancing two public interests.

First: Public-health efficiency.

Morocco must ensure that vaccines reach hospitals, rural communities, vaccination centres and other healthcare facilities safely and without unnecessary delay.

Second: Competitive market access.

Pharmaceutical distributors and logistics operators must have a genuine opportunity to compete for transportation, storage and supply contracts.

An arrangement that divides territories may sometimes appear administratively efficient. However, if competing companies agree to eliminate competition between themselves, the arrangement can become a cartel.

Conversely, requiring every company to independently operate every route could increase costs, duplicate infrastructure and undermine vaccine delivery.

The appropriate legal approach is therefore to distinguish legitimate operational cooperation from anti-competitive market allocation.

Article 9 is especially important in evaluating efficiency-based justifications, but public-health benefits do not automatically exempt an agreement from competition law.

12. Conclusion

Competition Law in Vaccine Route Allocation in Morocco is an important intersection of pharmaceutical regulation, public procurement, logistics management and market competition.

Articles 6 and 7 of Law No. 104-12 provide the principal legal foundation for examining geographical market division, bid rigging, discriminatory distribution arrangements, exclusionary conduct and abuse of dominant positions.

The comparative decisions in Consten and Grundig, Société Technique Minière, United Brands, Commercial Solvents, Oscar Bronner, T-Mobile Netherlands, United States v Sealy and Palmer v BRG provide useful legal principles for analysing these problems.

The Belgian influenza-vaccine cartel enforcement example is particularly relevant because it demonstrates how anti-competitive coordination can arise directly within vaccine distribution.

Ultimately, Morocco should promote a vaccine distribution system that combines transparent geographical allocation, independent commercial decision-making, fair procurement, reliable cold-chain infrastructure and uninterrupted public-health delivery.

13. Important Legal Authorities and Case Reference List

Research qualification: These authorities provide a comparative legal framework. The Belgian vaccine cartel is a direct vaccine-distribution enforcement example, not a Moroccan court precedent. No specific reported Moroccan judgment directly deciding vaccine transportation route allocation is identified here.

This is an academic legal analysis, not a substitute for advice on a particular Moroccan procurement or distribution agreement.